2025-11-17T15:32:34-05:00 2024-12-31 274760605 KULLMAN CPA LLC 888 BESTGATE ROAD SUITE 316 ANNAPOLIS MD 21401 990 2024-01-01 814713372 MILA'S MIRACLE FOUNDATION MILA 2165131205 PO BOX 19675 BOULDER CO 80308 JULIA VITARELLO PRESIDENT 2165135201 2025-11-14 true true STEPHEN J KULLMAN CPA P00308157 4102669885 2025-11-14 2024 2025-03-06 01:10:19Z JULIA VITARELLO PO BOX 19675 BOULDER CO 80308 706872 false X WWW.STOPBATTEN.ORG X 2016 DE THE MISSION OF MILA'S MIRACLE FOUNDATION IS TO FIND AND FUND PATHS TO A CURE FOR BATTEN AND OTHER LIFE-THREATENING NEUROLOGICAL DISORDERS. FAMILIES IN THIS COMMUNITY HAVE BEEN PIVOTAL IN RAISING THE NECESSARY FUNDS AND AWARENESS. TOGETHER, WITH OUR INCREDIBLE SCIENTISTS AND PARTNER ORGANIZATIONS, WE HOPE THAT OUR WORK WILL IMPROVE THE PROGNOSIS OF BATTEN DISEASE AND OTHER NEURODEGENERATIVE DISEASES. THROUGH OUR FUNDRAISING - WHICH INCLUDES GRASSROOTS EFFORTS, INDIVIDUALS AND FAMILY FOUNDATIONS, AND GRANTS - OUR FOUNDATION WORK HAS FOCUSED ON THE FOLLOWING PROGRAM INITIATIVES TO DATE: THE EXPANSION OF INDIVIDUALIZED MEDICINES; CLINICAL TRIALS & PROGRAMS, INCLUDING AN ANTISENSE OLIGONUCLEOTIDE (ASO) CLINICAL TRIAL, A CLN7 GENE THERAPY TRIAL, AND A BATTEN & NEURODEGENERATIVE DISEASE CLINIC; AND BASIC SCIENCE RESEARCH FOR BATTEN DISEASE, INCLUDING A PEDIATRIC CELL ATLAS OF BATTEN PATHOBIOLOGY AND THERAPEUTIC RESPONSE. 5 5 2 0 21412 706839 0 75 33 0 21487 706872 0 0 188027 200181 0 11949 204081 292826 392108 493007 -370621 213865 270092 483957 0 270092 483957 X THE MISSION OF MILA'S MIRACLE FOUNDATION IS TO FIND AND FUND PATHS TO A CURE FOR BATTEN AND OTHER LIFE-THREATENING NEUROLOGICAL DISORDERS. FAMILIES IN THIS COMMUNITY HAVE BEEN PIVOTAL IN RAISING THE NECESSARY FUNDS AND AWARENESS. TOGETHER, WITH OUR INCREDIBLE SCIENTISTS AND PARTNER ORGANIZATIONS, WE HOPE THAT OUR WORK WILL IMPROVE THE PROGNOSIS OF BATTEN DISEASE AND OTHER NEURODEGENERATIVE DISEASES. THROUGH OUR FUNDRAISING - WHICH INCLUDES GRASSROOTS EFFORTS, INDIVIDUALS AND FAMILY FOUNDATIONS, AND GRANTS - OUR FOUNDATION WORK HAS FOCUSED ON THE FOLLOWING PROGRAM INITIATIVES TO DATE: THE EXPANSION OF INDIVIDUALIZED MEDICINES; CLINICAL TRIALS & PROGRAMS, INCLUDING AN ANTISENSE OLIGONUCLEOTIDE (ASO) CLINICAL TRIAL, A CLN7 GENE THERAPY TRIAL, AND A BATTEN & NEURODEGENERATIVE DISEASE CLINIC; AND BASIC SCIENCE RESEARCH FOR BATTEN DISEASE, INCLUDING A PEDIATRIC CELL ATLAS OF BATTEN PATHOBIOLOGY AND THERAPEUTIC RESPONSE. false false 275970 EXPANSION OF INDIVIDUALIZED MEDICINES - AT PRESENT, THE FOUNDATION IS FOCUSED ON HELPING TO GROW THE NEW FIELD OF INDIVIDUALIZED MEDICINES, WHICH MILA'S STORY FIRST OPENED UP. ALONGSIDE MILA'S DOCTOR (DR. TIMOTHY YU) AND HIS TEAM AT BOSTON CHILDREN'S HOSPITAL, WE ARE WORKING COLLABORATIVELY WITH LEADERS IN THE FIELD TO RETHINK THE DRUG DEVELOPMENT PROCESS SO WE CAN SAFELY AND RAPIDLY SCALE N-OF-1 TREATMENTS AND ADDRESS THE GLOBAL HEALTH CRISIS OF RARE GENETIC DISEASES. OUR "MILA TO MILLIONS" INITIATIVE IS PRIORITIZING TWO KEY AREAS TO SUCCESSFULLY BRIDGE THE GAP BETWEEN THE NEED FOR TREATMENTS, THE EXISTING TECHNOLOGY TO DEVELOP THEM, AND THE MISSING INFRASTRUCTURE TO EXPAND ACCESS TO THEM. OUR STRATEGIC PILOTS IN THE UK AND US ARE AIMED AT PROVIDING NEW MODELS OF ACCESS TO INDIVIDUALIZED MEDICINES, AND OUR IMPACT CAMPAIGN IS AIMED AT SHIFTING THE PUBLIC MINDSET TO INFLUENCE THE CRITICAL DECISIONS NEEDED TO PAVE THIS PATHWAY FORWARD. OUR HOPE IS TO GO FROM MILA TO MILLIONS, MAKING INDIVIDUALIZED MEDICINES ACCESSIBLE TO MANY MORE CHILDREN ACROSS THOUSANDS OF RARE DISEASES. 165565 BASIC SCIENCE RESEARCH - TO DATE, THE FOUNDATION HAS FUNDED THREE (4) BASIC SCIENCE RESEARCH PROJECTS FOR BATTEN DISEASE IN THE US, EUROPE AND AUSTRALIA. BY SUPPORTING SCIENTISTS WORKING TO CRACK THE CLN7 GENE (AS WELL AS OTHER VARIANTS OF BATTEN DISEASE) THROUGH MEETINGS WITH RESEARCHERS AND PHYSICIANS, AND GRANT FUNDING TO LABS WORKING ON BIOMARKER DISCOVERY AND DATA COLLECTION, WE ARE LEARNING MORE ABOUT THIS DEVASTATING CHILDHOOD CONDITION WITH THE HOPE OF IMPROVING FUTURE TREATMENT OPTIONS. EARLY RESEARCH PROJECTS FUNDED BY THE FOUNDATION HAVE LED TO FINDINGS AND RESULTS PUBLISHED IN THE JOURNAL OF CLINICAL INVESTIGATION, WHICH DEMONSTRATE THAT AN "AAV9/MFSD8 GENE THERAPY IS EFFECTIVE IN PRE-CLINICAL MODELS OF NEURONAL CEROID LIPOFUSCINOSIS TYPE 7 DISEASE". ADDITIONALLY, DONATED TISSUE SAMPLES, FUNDING, AND PATIENT-PARTNERED RESEARCH SUPPORT PROVIDED BY THE FOUNDATION LED TO THE CREATION OF THE FIRST-EVER PEDIATRIC CELL ATLAS OF BATTEN PATHOBIOLOGY AND THERAPEUTIC RESPONSE. THE FOUNDATION'S WORK ON THE CELL ATLAS IS STILL ONGOING AND SUBSEQUENTLY LED TO THE LAUNCH OF THE "LITTLE LEGACIES" BRAIN DONATION PROGRAM WHICH IS BEING OVERSEEN BY THE FOUNDATION IN PARTNERSHIP WITH BOSTON CHILDREN'S HOSPITAL, THE UNIVERSITY OF MARYLAND, THE BRAIN DONOR PROJECT AND THE CHAN ZUCKERBERG INITIATIVE. 1799 CLINICAL TRIALS & PROGRAMS - TO DATE, THE FOUNDATION HAS FUNDED TWO (2) CLINICAL TRIALS AND ONE (1) CLINICAL PROGRAM FOR CHILDREN WITH BATTEN DISEASE: 1.) AN ANTISENSE OLIGONUCLEOTIDE (ASO) CLINICAL TRIAL - THE FOUNDATION PARTNERED WITH BOSTON CHILDREN'S HOSPITAL TO FUND, DEVELOP, AND ADMINISTER MILASEN, THE FIRST-EVER INDIVIDUALIZED MEDICINE DESIGNED FOR ONE PERSON. LED BY THE PIONEERING SCIENTIST/NEUROLOGIST, DR. TIMOTHY YU, THIS ASO TREATMENT, WHICH MILA RECEIVED FOR THREE YEARS, TARGETED HER INDIVIDUAL DISEASE-CAUSING MUTATION AND PROVED THAT NOVEL TREATMENTS SIMILAR TO THIS COULD BE DEVELOPED AND DEPLOYED TO TREAT CHILDREN AFFECTED BY A NUMBER OF OTHER RARE GENETIC DISORDERS. 2.) A CLN7 GENE THERAPY TRIAL - TOGETHER, WITH RENOWNED GENE THERAPIST DR. STEVEN GRAY, THE FOUNDATION BEGAN THE WORK ON A NOVEL GENE THERAPY DIRECT TO THE BRAIN FOR CHILDREN WITH MILA'S VARIANT OF BATTEN DISEASE, CLN7. THIS PROMISING APPROACH REPLACES THE BROKEN GENE WITH HE CORRECT ONE IN A ONE-TIME SHOT INTO THE CEREBROSPINAL FLUID. THE TRIAL WAS DEVELOPED IN PARTNERSHIP WITH UT SOUTHWESTERN, AASHI'S HOPE AND BATTEN HOPE, AND LAUNCHED IN SPRING 2021. 3.) NEURODEGENERATIVE DISEASE CLINIC - THE FOUNDATION HELPED FUND AND LAUNCH A BATTEN & NEUROLOGICAL DISEASE CLINIC AT CHILDREN'S HOSPITAL COLORADO IN 2020. THE PURPOSE OF ESTABLISHING THIS CENTER OF EXCELLENCE WAS TO PROVIDE FAMILIES WITH CHILDREN AFFECTED BY NEURODEGENERATIVE DISEASES A PLACE TO RECEIVE SPECIALIZED MULTIDISCIPLINARY CARE ALL IN ONE VISIT DURING A SINGLE APPOINTMENT CONDUCTED ANNUALLY AND/OR SEMI-ANNUALLY, BASED ON THE CHILD'S PERSONALIZED CARE PLAN. SIMULTANEOUSLY, RESEARCH DATA IS COLLECTED TO HELP BETTER UNDERSTAND THESE DISEASES AND EVENTUALLY INFORM FUTURE TREATMENT PATHS. 443334 true true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true 1 0 2 true false false false false true true false false false false false false false X 5 5 true false false false false false false true true false false true true true true false true true false false CO X X MARGARET SPOTH 2165135201 2641 SHAKER ROAD CLEVELAND HEIGHTS OH 44118 JULIA VITARELLO PRESIDENT 40.00 X X 113470 0 0 JULIE MITCHELL CHAIR 1.00 X X 0 0 0 ADAM VITARELLO VICE CHAIR 1.00 X X 0 0 0 LORI SAMES TREASURER 1.00 X X 0 0 0 KATHERINE FOX NAGEL SECRETARY 1.00 X X 0 0 0 SARAH COTTINGHAM BOARD MEMBER 1.00 X 0 0 0 113470 1 false false false 576842 129997 706839 33 33 706872 33 X 185403 166417 7965 11021 14778 13392 576 810 6600 6600 246487 241998 4489 8904 1398 7506 632 23 491 118 18194 17640 554 2048 2048 DUES & SUBSCRIPTIONS 8750 2466 6284 BANK FEES 1016 1016 TAXES & LICENSES 195 195 493007 443334 37724 11949 46201 157346 223891 325923 688 270092 483957 0 0 X 270092 150305 333652 270092 483957 270092 483957 213865 X true X false true false X 193610 263117 649773 21412 706839 1834751 193610 263117 649773 21412 706839 1834751 930003 904748 400 138 86 75 33 732 1835483 45500 0.49290 0.35620 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED FORM 990 - ORGANIZATION'S MISSION THE MISSION OF MILA'S MIRACLE FOUNDATION IS TO FIND AND FUND PATHS TO A CURE FOR BATTEN AND OTHER LIFE-THREATENING NEUROLOGICAL DISORDERS. FAMILIES IN THIS COMMUNITY HAVE BEEN PIVOTAL IN RAISING THE NECESSARY FUNDS AND AWARENESS. TOGETHER, WITH OUR INCREDIBLE SCIENTISTS AND PARTNER ORGANIZATIONS, WE HOPE THAT OUR WORK WILL IMPROVE THE PROGNOSIS OF BATTEN DISEASE AND OTHER NEURODEGENERATIVE DISEASES. THROUGH OUR FUNDRAISING - WHICH INCLUDES GRASSROOTS EFFORTS, INDIVIDUALS AND FAMILY FOUNDATIONS, AND GRANTS - OUR FOUNDATION WORK HAS FOCUSED ON THE FOLLOWING PROGRAM INITIATIVES TO DATE: THE EXPANSION OF INDIVIDUALIZED MEDICINES; CLINICAL TRIALS & PROGRAMS, INCLUDING AN ANTISENSE OLIGONUCLEOTIDE (ASO) CLINICAL TRIAL, A CLN7 GENE THERAPY TRIAL, AND A BATTEN & NEURODEGENERATIVE DISEASE CLINIC; AND BASIC SCIENCE RESEARCH FOR BATTEN DISEASE, INCLUDING A PEDIATRIC CELL ATLAS OF BATTEN PATHOBIOLOGY AND THERAPEUTIC RESPONSE. FORM 990, PAGE 2, PART III, LINE 4A EXPANSION OF INDIVIDUALIZED MEDICINES - AT PRESENT, THE FOUNDATION IS FOCUSED ON HELPING TO GROW THE NEW FIELD OF INDIVIDUALIZED MEDICINES, WHICH MILA'S STORY FIRST OPENED UP. ALONGSIDE MILA'S DOCTOR (DR. TIMOTHY YU) AND HIS TEAM AT BOSTON CHILDREN'S HOSPITAL, WE ARE WORKING COLLABORATIVELY WITH LEADERS IN THE FIELD TO RETHINK THE DRUG DEVELOPMENT PROCESS SO WE CAN SAFELY AND RAPIDLY SCALE N-OF-1 TREATMENTS AND ADDRESS THE GLOBAL HEALTH CRISIS OF RARE GENETIC DISEASES. OUR "MILA TO MILLIONS" INITIATIVE IS PRIORITIZING TWO KEY AREAS TO SUCCESSFULLY BRIDGE THE GAP BETWEEN THE NEED FOR TREATMENTS, THE EXISTING TECHNOLOGY TO DEVELOP THEM, AND THE MISSING INFRASTRUCTURE TO EXPAND ACCESS TO THEM. OUR STRATEGIC PILOTS IN THE UK AND US ARE AIMED AT PROVIDING NEW MODELS OF ACCESS TO INDIVIDUALIZED MEDICINES, AND OUR IMPACT CAMPAIGN IS AIMED AT SHIFTING THE PUBLIC MINDSET TO INFLUENCE THE CRITICAL DECISIONS NEEDED TO PAVE THIS PATHWAY FORWARD. OUR HOPE IS TO GO FROM MILA TO MILLIONS, MAKING INDIVIDUALIZED MEDICINES ACCESSIBLE TO MANY MORE CHILDREN ACROSS THOUSANDS OF RARE DISEASES. FORM 990, PAGE 2, PART III, LINE 4B BASIC SCIENCE RESEARCH - TO DATE, THE FOUNDATION HAS FUNDED THREE (4) BASIC SCIENCE RESEARCH PROJECTS FOR BATTEN DISEASE IN THE US, EUROPE AND AUSTRALIA. BY SUPPORTING SCIENTISTS WORKING TO CRACK THE CLN7 GENE (AS WELL AS OTHER VARIANTS OF BATTEN DISEASE) THROUGH MEETINGS WITH RESEARCHERS AND PHYSICIANS, AND GRANT FUNDING TO LABS WORKING ON BIOMARKER DISCOVERY AND DATA COLLECTION, WE ARE LEARNING MORE ABOUT THIS DEVASTATING CHILDHOOD CONDITION WITH THE HOPE OF IMPROVING FUTURE TREATMENT OPTIONS. EARLY RESEARCH PROJECTS FUNDED BY THE FOUNDATION HAVE LED TO FINDINGS AND RESULTS PUBLISHED IN THE JOURNAL OF CLINICAL INVESTIGATION, WHICH DEMONSTRATE THAT AN "AAV9/MFSD8 GENE THERAPY IS EFFECTIVE IN PRE-CLINICAL MODELS OF NEURONAL CEROID LIPOFUSCINOSIS TYPE 7 DISEASE". ADDITIONALLY, DONATED TISSUE SAMPLES, FUNDING, AND PATIENT-PARTNERED RESEARCH SUPPORT PROVIDED BY THE FOUNDATION LED TO THE CREATION OF THE FIRST-EVER PEDIATRIC CELL ATLAS OF BATTEN PATHOBIOLOGY AND THERAPEUTIC RESPONSE. THE FOUNDATION'S WORK ON THE CELL ATLAS IS STILL ONGOING AND SUBSEQUENTLY LED TO THE LAUNCH OF THE "LITTLE LEGACIES" BRAIN DONATION PROGRAM WHICH IS BEING OVERSEEN BY THE FOUNDATION IN PARTNERSHIP WITH BOSTON CHILDREN'S HOSPITAL, THE UNIVERSITY OF MARYLAND, THE BRAIN DONOR PROJECT AND THE CHAN ZUCKERBERG INITIATIVE. FORM 990, PAGE 2, PART III, LINE 4C CLINICAL TRIALS & PROGRAMS - TO DATE, THE FOUNDATION HAS FUNDED TWO (2) CLINICAL TRIALS AND ONE (1) CLINICAL PROGRAM FOR CHILDREN WITH BATTEN DISEASE: 1.) AN ANTISENSE OLIGONUCLEOTIDE (ASO) CLINICAL TRIAL - THE FOUNDATION PARTNERED WITH BOSTON CHILDREN'S HOSPITAL TO FUND, DEVELOP, AND ADMINISTER MILASEN, THE FIRST-EVER INDIVIDUALIZED MEDICINE DESIGNED FOR ONE PERSON. LED BY THE PIONEERING SCIENTIST/NEUROLOGIST, DR. TIMOTHY YU, THIS ASO TREATMENT, WHICH MILA RECEIVED FOR THREE YEARS, TARGETED HER INDIVIDUAL DISEASE-CAUSING MUTATION AND PROVED THAT NOVEL TREATMENTS SIMILAR TO THIS COULD BE DEVELOPED AND DEPLOYED TO TREAT CHILDREN AFFECTED BY A NUMBER OF OTHER RARE GENETIC DISORDERS. 2.) A CLN7 GENE THERAPY TRIAL - TOGETHER, WITH RENOWNED GENE THERAPIST DR. STEVEN GRAY, THE FOUNDATION BEGAN THE WORK ON A NOVEL GENE THERAPY DIRECT TO THE BRAIN FOR CHILDREN WITH MILA'S VARIANT OF BATTEN DISEASE, CLN7. THIS PROMISING APPROACH REPLACES THE BROKEN GENE WITH HE CORRECT ONE IN A ONE-TIME SHOT INTO THE CEREBROSPINAL FLUID. THE TRIAL WAS DEVELOPED IN PARTNERSHIP WITH UT SOUTHWESTERN, AASHI'S HOPE AND BATTEN HOPE, AND LAUNCHED IN SPRING 2021. 3.) NEURODEGENERATIVE DISEASE CLINIC - THE FOUNDATION HELPED FUND AND LAUNCH A BATTEN & NEUROLOGICAL DISEASE CLINIC AT CHILDREN'S HOSPITAL COLORADO IN 2020. THE PURPOSE OF ESTABLISHING THIS CENTER OF EXCELLENCE WAS TO PROVIDE FAMILIES WITH CHILDREN AFFECTED BY NEURODEGENERATIVE DISEASES A PLACE TO RECEIVE SPECIALIZED MULTIDISCIPLINARY CARE ALL IN ONE VISIT DURING A SINGLE APPOINTMENT CONDUCTED ANNUALLY AND/OR SEMI-ANNUALLY, BASED ON THE CHILD'S PERSONALIZED CARE PLAN. SIMULTANEOUSLY, RESEARCH DATA IS COLLECTED TO HELP BETTER UNDERSTAND THESE DISEASES AND EVENTUALLY INFORM FUTURE TREATMENT PATHS. FORM 990, PAGE 6, PART VI, LINE 2 JULIA VITARELLO ADAM VITARELLO PRESIDENT VICE CHAIR FAMILY RELATIONSHIP FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF FORM 990 WILL BE PROVIDED TO EACH MEMBER OF THE GOVERNING BODY, VIA EMAIL OR AT A BOARD MEETING, PRIOR TO SUBMISSION TO THE INTERNAL REVENUE SERVICE. FORM 990, PAGE 6, PART VI, LINE 12C MEMBERS OF THE BOARD ARE ASKED TO DISCLOSE AND PRESENT ON POTENTIAL CONFLICTS TO THE FULL BOARD OF DIRECTORS DURING REGULARLY SCHEDULED MEETINGS. MEETINGS ADJOURN TO AN EXECUTIVE SESSION, AS NOTED IN THE MINUTES, AT WHICH TIME THE REMAINING DIRECTORS REVIEW, DISCUSS AND VOTE TO DETERMINE IF A CONFLICT OF INTEREST EXISTS AND IF ANY FURTHER ACTION NEEDS TO BE TAKEN. DIRECTORS AND OFFICERS ARE ASKED TO SIGN AN AFFIRMATION STATEMENT ANNUALLY AND CONDUCT PERIODIC REVIEWS TO ENSURE THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH CHARITABLE PURPOSES AND DOES NOT ENGAGE IN ACTIVITIES THAT COULD JEOPARDIZE ITS TAX-EXEMPT STATUS. FORM 990, PAGE 6, PART VI, LINE 15A THE MMF BOARD OF DIRECTORS (EXCLUDING JULIA VITARELLO) REVIEWED AND APPROVED JULIA'S SALARY (AS CEO), MAGGIE'S SALARY (AS KEY EMPLOYEE), AND CHRIS' SALARY (AS CONTRACT WORKER) VIA WRITTEN CONSENT (IN LIEU OF MEETING) THAT LAST TOOK PLACE ON AUGUST 16, 2024. THE APPROVED ACTIONS VIA WRITTEN CONSENT WERE THEN DOCUMENTED IN THE MINUTES OF THE NEXT BOARD MEETING WHICH TOOK PLACE ON SEPTEMBER 11, 2024. LEADING UP TO THE APPROVAL, THE NONFAMILY MEMBERS OF THE MMF BOARD OF DIRECTORS PARTICIPATED IN PRIVATE DISCUSSIONS TO DETERMINE A BASIS FOR JULIA'S SALARY, AND SEPERATE DISCUSSIONS TOOK PLACE BETWEEN JULIA AND THE OTHER MMF BOARD MEMBERS TO DETERMINE A BASIS FOR MAGGIE AND CHRIS' SALARIES. THE PROCESS USED TO ESTABLISH REASONABLE COMPENSATION WAS DETERMINED BY SEVERAL FACTORS INCLUDING, BUT NOT LIMITED TO: CENSUS DATA AND COMPENSATION REPORTS FOR COMPARABLE INDUSTRY POSITIONS, ANNUAL COST OF LIVING ADJUSTMENTS, JOB DESCRIPTION, ANNUAL PERFORMANCE REVIEW, ORG BUDGET. FORM 990, PAGE 6, PART VI, LINE 19 GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G ADMINISTRATION EXPENSES:PROFE 0 4,489 0 PROFESSIONAL FEES - PGM:OTHER 100,000 0 0 EMPLOYEE EXPENSES - PGM:COMPE 56,000 0 0 PROFESSIONAL FEES - PGM:VIDEO 70,000 0 0 PROFESSIONAL FEES - PGM:PHOTO 11,381 0 0 PROFESSIONAL FEES - PGM:EQUIP 2,617 0 0 TRIAL COSTS - PGM:BASIC SCIEN 2,000 0 0 TOTAL 241,998 4,489 0